10-K: Pro-Dex Inc. Reports Fiscal Year 2024 Results, Revenue Up 17% Despite Backlog Decline

Pro-Dex, Inc. saw a 17% increase in revenue for fiscal year 2024, driven by growth in medical device sales and repairs, despite a significant decrease in backlog.

Summary

• Pro-Dex, Inc. reported a 17% increase in net sales for fiscal year 2024, reaching $53.8 million compared to $46.1 million in fiscal year 2023.
• The increase was primarily driven by a 20% rise in medical device sales and a 31% increase in repair revenue.
• Medical device sales reached $37 million, with growth across orthopedic, craniomaxillofacial (CMF), and thoracic segments.
• Repair revenue increased to $16.5 million due to enhanced repairs of orthopedic handpieces.
• The company's backlog decreased from $41.6 million in June 2023 to $19.8 million in June 2024, which is attributed to the timing of customer orders.
• Despite the backlog decrease, Pro-Dex does not expect a reduction in fiscal 2025 revenue compared to fiscal 2024.
• The company experienced a net loss of $4.5 million in other income (expense) due to unrealized losses on investments.
• Net income for fiscal year 2024 was $2.1 million, a decrease from $7.1 million in fiscal year 2023.
• The company repurchased 184,901 shares of its common stock at a cost of $3.5 million during fiscal year 2024.

Sentiment

Score: 5

Explanation: The document presents mixed results. While revenue increased, net income decreased significantly, and there are concerns about backlog and internal controls. The company is facing challenges but also has growth opportunities.

Positives

• The company experienced a significant increase in revenue, driven by strong performance in medical device sales and repairs.
• The company has a strong customer base with long-term supply agreements.
• The company has invested in a new facility to support future growth.
• The company has a strong focus on research and development to maintain its market position.
• The company has a share repurchase program in place.

Negatives

• The company experienced a significant decrease in backlog, which could impact future revenue.
• The company experienced a net loss of $4.5 million in other income (expense) due to unrealized losses on investments.
• The company's net income decreased significantly compared to the previous year.
• The company identified material weaknesses in its internal control over financial reporting related to inventory accounting and the valuation of investments.
• The company is heavily reliant on a few key customers, with one customer accounting for 71% of sales.

Risks

• The company is heavily reliant on a few key customers, and the loss of a major customer could have a material adverse effect.
• The company faces significant competition from larger companies with greater resources.
• The company's operations are subject to complex government regulations, and non-compliance could result in penalties.
• The company's technology infrastructure is vulnerable to cybersecurity incidents, which could disrupt operations.
• The company's debt obligations impose restrictions on its business and could limit its ability to take advantage of opportunities.
• The company has identified material weaknesses in its internal control over financial reporting, which could lead to misstatements in financial statements.
• The company's investments are subject to market fluctuations and could result in losses.

Future Outlook

The company does not expect a reduction in fiscal 2025 revenue compared to fiscal 2024 and believes the decline in backlog is related to the timing of customer orders. The company is focused on preserving cash balances by monitoring expenses and investing in programs that will contribute to profitability.

Management Comments

• Management believes that the efforts completed to bring the new facility operational will allow ample capacity to increase revenues significantly in future years.
• Management believes that the decline in backlog at June 30, 2024 compared to June 30, 2023 is related to timing of customer orders.
• Management believes that the company's existing cash and cash equivalent balances, together with account receivable balances, and anticipated cash flows from operations will provide sufficient funds to satisfy cash requirements for at least the next 12 months.

Industry Context

The medical device industry is highly competitive and subject to rapid technological change. Pro-Dex competes with larger companies and must continually innovate to maintain its market position. The company's focus on proprietary technology and customer relationships is crucial for its success in this environment.

Comparison to Industry Standards

• Pro-Dex's revenue growth of 17% is a strong result compared to the average growth rate in the medical device industry, which is typically in the single-digit range.
• The company's reliance on a few key customers is a common risk in the medical device contract manufacturing sector, where long-term relationships are often crucial.
• The decrease in backlog is a concern, as it could indicate a potential slowdown in future orders, which is a risk that many companies in this sector face.
• The company's investment in a new facility is a positive sign of its commitment to growth, which is a common strategy for companies in this sector.
• The company's focus on research and development is essential for maintaining a competitive edge in the rapidly evolving medical device market, similar to other companies in the sector such as Integer Holdings Corporation and Orchid Orthopedic Solutions.

Corporate Governance

Related Party Transactions

• Two board members, Messrs. Swenson and Cabillot, are also board members of Air T, Inc. and both either individually or through affiliates own an equity interest in Air T, Inc.
• Mr. Swenson, our Chairman, also serves as the chief executive officer and chairman of Air T, Inc.
• Another of our Board members is employed by Air T as its Chief of Staff.
• Our Chief Executive Officer, Richard Van Kirk (Rick), is also a Monogram board member.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and the material weaknesses in internal control.
• Employees may be affected by the company's efforts to control expenses and improve internal controls.
• Customers may be impacted by the company's ability to meet demand and maintain product quality.
• Suppliers may be affected by the company's efforts to manage costs and inventory.

Next Steps

• The company will continue to focus on product development and customer relationships.
• The company will work to address the material weaknesses in internal control over financial reporting.
• The company will monitor expenses and invest in programs that will contribute to profitability.
• The company will continue to execute its share repurchase program.

Key Dates

Keywords

medical devices, surgical instruments, orthopedic, craniomaxillofacial, thoracic, repairs, revenue, backlog, financial results, manufacturing, Minnesota Bank & Trust, share repurchase, internal controls, investments